Commentary on "Atezolizumab as first-line therapy in elderly patients with NSCLC"

被引：0
|
作者：
Schulz, Christian [1 ,2 ]
机构：
[1] Univ Klinikum Regensburg, Lungen Krebs Zent, Klin & Poliklin Innere Med 2, Bereich Pneumol, Regensburg, Germany
[2] Univ Klinikum Regensburg, Klin & Poliklin Innere Med 2, Bereich Pneumol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany
来源：
PNEUMOLOGIE | 2024年 / 78卷 / 05期
关键词：
D O I：
10.1055/a-2253-3857
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Commentary on "Atezolizumab as first-line therapy in elderly patients with NSCLC"
    Schulz, Christian
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (03) : 74 - 75
  • [2] Atezolizumab as first-line therapy in elderly patients with NSCLC
    Franke, Katharina
    [J]. PNEUMOLOGIE, 2024, 78 (05): : 287 - 287
  • [3] Atezolizumab as first-line therapy in elderly patients with NSCLC
    Franke, Katharina
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (03) : 75 - 75
  • [4] Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
    Sohita Dhillon
    Yahiya Y. Syed
    [J]. Targeted Oncology, 2019, 14 : 759 - 768
  • [5] Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
    Dhillon, Sohita
    Syed, Yahiya Y.
    [J]. TARGETED ONCOLOGY, 2019, 14 (06) : 759 - 768
  • [6] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    Socinski, M. A.
    Jotte, R. M.
    Cappuzzo, F.
    Orlandi, F.
    Stroyakovskiy, D.
    Nogami, N.
    Rodriguez-Abreu, D.
    Moro-Sibilot, D.
    Thomas, C. A.
    Barlesi, F.
    Finley, G.
    Kelsch, C.
    Lee, A.
    Coleman, S.
    Deng, Y.
    Shen, Y.
    Kowanetz, M.
    Lopez-Chavez, A.
    Sandler, A.
    Reck, M.
    Ahualli, A.
    Jarchum, G.
    Kaen, D. L.
    Kahl, S.
    Kotliar, M.
    Kowalyszyn, R. D.
    Lerzo, G.
    Magri, I
    Martin, C.
    Pastor, A.
    Picon, P.
    Streich, G.
    Varela, M.
    Blinman, P.
    Boyer, M.
    Crombie, C.
    Gauden, S.
    Gill, S.
    Hughes, B.
    John, T.
    Joshi, A.
    Kosmider, S.
    Lewis, C.
    Millward, M.
    Nordman, I
    Nott, L.
    O'Byrne, K.
    Parnis, F.
    Potasz, N.
    Richardson, G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24): : 2288 - 2301
  • [7] A first for first-line therapy in NSCLC
    Rebecca Kirk
    [J]. Nature Reviews Clinical Oncology, 2011, 8 (12) : 691 - 691
  • [8] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
    Herbst, Roy S.
    Giaccone, Giuseppe
    de Marinis, Filippo
    Reinmuth, Niels
    Vergnenegre, Alain
    Barrios, Carlos H.
    Morise, Masahiro
    Felip, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozguroglu, Mustafa
    Zou, Wei
    Sandler, Alan
    Enquist, Ida
    Komatsubara, Kimberly
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    McCleland, Mark
    Mocci, Simonetta
    Jassem, Jacek
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14): : 1328 - 1339
  • [9] Lenalidomide as first-line therapy for elderly CLL patients
    Gilbert, Judith A.
    [J]. LANCET ONCOLOGY, 2013, 14 (09): : E345 - E345
  • [10] Bevacizumab in the first-line therapy of advanced NSCLC
    Hasenoehrl, Norbert
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
12345